Lupin Diagnostics achieves NABL Accreditation for All Greenfield Labs

Lupin Diagnostics Limited (LDL), a wholly owned subsidiary of global pharma major Lupin Limited (Lupin) has achieved 100% NABL (National Accreditation Board for Testing and Calibration Laboratories) accreditation across all its greenfield labs.

"This accreditation is a testament to the team's dedication to patient care and our mission to promote healthier lives. The 27 greenfield labs across the country ensure timely and accurate reporting. Our goal is to empower doctors and patients with evidence-based diagnostics," said Ravindra Kumar, CEO, Lupin Diagnostics. "We remain committed to enhancing healthcare through continuous improvement and innovation."

This notable achievement highlights the adherence to rigorous quality control measures, reinforcing LDL's unwavering dedication to providing top-tier diagnostic services. The company's commitment to quality is reflected in every aspect of its operations, ensuring patients receive accurate and timely results that they can trust.

Among its recent accolades, Lupin Diagnostics received the prestigious titles of 'Patient-Centric Diagnostic Laboratories Company of the Year' at the IHW 3rd Patients First Award 2024, 'Emerging Diagnostics Chain of the Year' at the Diagnostics Innovation and Excellence Award 2024 by Voice of Healthcare, and 'Pathology Lab of the Year' (National Category) at the ET Healthcare Awards in 2022 and 2024. These honors emphasize the company's dedication to patient-centered care and its leading position in the diagnostics industry.

Shares of Lupin Limited was last trading in BSE at Rs. 2088.85 as compared to the previous close of Rs. 2046.90. The total number of shares traded during the day was 160258 in over 10226 trades.

The stock hit an intraday high of Rs. 2103.35 and intraday low of 2035.15. The net turnover during the day was Rs. 334283435.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 LupinDiagnostics NABLAccreditation AllGreenfieldLabs